SAN DIEGO (AP) _ Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $20 million in its fourth quarter.
The San Diego-based company said it had a loss of 38 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share.
The biopharmaceutical company posted revenue of $18,000 in the period.
For the year, the company reported that its loss widened to $81.8 million, or $1.55 per share. Revenue was reported as $1.2 million.
In the final minutes of trading on Thursday, the company's shares hit $1.10. A year ago, they were trading at $7.23.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGLS at https://www.zacks.com/ap/RGLS
Keywords: Regulus, Earnings Report